OC-0342: Chemoradiotherapy in high-risk prostate cancer (QRT SOGUG trial): Preliminary report

Arnalot, Palmira Foro; Maldonado, X.; Bonet, Marta; Jové, Josep; Rovirosa, Á.; Rico, Miguel Toscano; Bejar, A.; Sancho, Gemma; Vega, Melina; Mira, M.; Martínez, Maite; Algara, M.; Carles, Joan

doi:10.1016/s0167-8140(16)31591-2

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, a phase II trial (NCT02506114) is evaluating the efficacy of a PSA-based form of immunization, with or without additional immunotherapy with ipilimumab, prior to definitive local treatment with RP for high-risk PCa. This is not to say that traditional chemotherapeutic regimens have been overlooked, however; the QRT-SOGUG phase II trial (NCT03432780), of which a preliminary report of results was published in abstract format in 2016, is investigating the safety and efficacy of administering weekly docetaxel concurrently with standard dosing of RT and ADT (87). In addition, there is interest in adapting hormone therapy regimens to incorporate the newest generation of drugs such as apalutamide and abiraterone; the phase II trial NCT02949284 is a trial that is examining the feasibility of performing nerve-sparing RP in the setting of apalutamide given either alone or in combination with abiraterone and prednisone.…”

Section: Current Prospective Trials Of Interestmentioning

confidence: 99%

Combined Modality Therapies for High-Risk Prostate Cancer: Narrative Review of Current Understanding and New Directions

2019

View full text Add to dashboard Cite

Despite the many prospective randomized trials that have been available in the past decade regarding the optimization of radiation, hormonal, and surgical therapies for high-risk prostate cancer (PCa), many questions remain. There is currently a lack of level I evidence regarding the relative efficacy of radical prostatectomy (RP) followed by adjuvant radiation compared to radiation therapy (RT) combined with androgen deprivation therapy (ADT) for high-risk PCa. Current retrospective series have also described an improvement in biochemical outcomes and PCa-specific mortality through the use of augmented radiation strategies incorporating brachytherapy. The relative efficacy of modern augmented RT compared to RP is still incompletely understood. We present a narrative review regarding recent advances in understanding regarding comparisons of overall and PCa-specific mortality measures among patients with high-risk PCa treated with either an RP/adjuvant RT or an RT/ADT approach. We give special consideration to recent trends toward the assembly of multi-institutional series targeted at providing high-quality data to minimize the effects of residual confounding. We also provide a narrative review of recent studies examining brachytherapy boost and systemic therapies, as well as an overview of currently planned and ongoing studies that will further elucidate strategies for treatment optimization over the next decade.

show abstract

Section: Current Prospective Trials Of Interestmentioning

confidence: 99%

Combined Modality Therapies for High-Risk Prostate Cancer: Narrative Review of Current Understanding and New Directions

2019

View full text Add to dashboard Cite

show abstract

Dose-escalated radiotherapy for clinically localized and locally advanced prostate cancer

Kim

Kong

Lee

et al. 2023

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer

et al. 2019

View full text Add to dashboard Cite

Context: Systemic therapies, combinedwith local treatment for high-risk prostate cancer, are recommended by the international guidelines for specific subgroups of patients; however, for many of the clinical scenarios, it remains a research field. Objective: To perform a systematic review, and describe current evidence and perspectives about the multimodal treatment of high-risk prostate cancer. Evidence acquisition: We performed a systematic review of PubMED, Embase, Cochrane Library, European Society of Medical Oncology/American Society of Clinical Oncology Annual proceedings, and clinicalTrial.gov between January 2010 and February 2018 following the Preferred Reporting Items for Systematic Reviews and Meta-analysis statement. Evidence synthesis: Seventy-seven prospective trials were identified. According to multiple randomized trials, combining androgen deprivation therapy (ADT) with external-beam radiotherapy (EBRT) outperforms EBRT alone for both relapse-free and overall survival. Neoadjuvant ADT did not show significant improvement compared with prostatectomy alone. The role of adjuvant ADT after prostatectomy in patients with high-risk disease is still debated, with lack of data from phase 3 trials in pNO patients. Novel androgen pathway inhibitors have been tested only in early-phase trials in addition to primary treatment. GETUG 12, RTOG 0521, and nonmetastatic subgroup of the STAMPEDE trial showed improved relapse-free survival for docetaxel in patients treated with EBRT plus ADT, although mature metastasis-free survival data are still pending. Both the SPCG-12 and the VACSP#553 trial showed no improvement in relapse free survival for adjuvant docetaxel after prostatectomy. Conclusions: In contrast to the clearly demonstrated survival benefits of long-term adjuvant ADT when used with EBRT, its role after prostatectomy remains unclear especially in pNO patients. Adding docetaxel to EBRT-ADT improves relapse-free survival, with immature results on overall survival. Novel androgen receptor pathway inhibitors are currently being tested in the neoadjuvant and adjuvant setting. Patient summary: Treatment of high-risk prostate cancer is based on a multimodality approach that includes systemic treatments. The best treatment or therapy combination remains to be defined.

show abstract

OC-0342: Chemoradiotherapy in high-risk prostate cancer (QRT SOGUG trial): Preliminary report

Cited by 3 publications

References 0 publications

Combined Modality Therapies for High-Risk Prostate Cancer: Narrative Review of Current Understanding and New Directions

Combined Modality Therapies for High-Risk Prostate Cancer: Narrative Review of Current Understanding and New Directions

Dose-escalated radiotherapy for clinically localized and locally advanced prostate cancer

Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer

Contact Info

Product

Resources

About